Author:
Otrebski Nilsson Mona,Aas Kirsti,Myklebust Tor Å.,Gjelsvik Ylva Maria,Haug Erik Skaaheim,Fosså Sophie D.,Johannesen Tom Børge
Abstract
Objective: In comparable men with non-metastatic prostate cancer, radical prostatectomy (RP), radiotherapy (RAD) and active surveillance (AS) are treatment options with similar survival rates, but different side-effects. Healthcare professionals consider pretreatment shared decision making (SDM) to be an essential part of medical care, though the patients’ view about SDM is less known. In this article, we explore prostate cancer (PCa) patients’ SDM wish (SDMwish), and experiences (SDMexp).
Material and methods: This is a registry-based survey performed by the Cancer Registry of Norway (2017–2019). One year after diagnosis, 5,063 curatively treated PCa patients responded to questions about their pre-treatment wish and experience regarding SDM. Multivariable analyses identified factors associated with SDM. Statistical significance level: p < 0.05.
Results: Overall, 78% of the patients wished to be involved in SDM and 83% of these had experienced SDM. SDMwish and SDMexp was significantly associated with decreasing age, increasing education, and living with a partner. Compared with the RP group, the probability of SDMwish and SDMexp was reduced by about 40% in the RAD and the AS groups.
Conclusion: Three of four curatively treated PCa wanted to participate in SDM, and this wish was met in four of five men. Younger PCa patients with higher education in a relationship, and opting for RP, wanted an active role in SDM, and experienced being involved. Effective SDM requires the responsible physicians’ attention to the individual patients’ characteristics and needs.
Publisher
Medical Journals Sweden AB
Reference28 articles.
1. Cancer Registry of Norway. Cancer in Norway 2021 – cancer incidence, mortality, survival and prevalence in Norway. 2022.[cited 2023 Feb 14]. Available from: https://www.kreftregisteret.no/globalassets/cancer-in-norway/2021/cin_report.pdf
2. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62. https://doi.org/10.1016/j.eururo.2020.09.042
3. Hamdy FC, Donovan JL, Lane JA, et al. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2023;388(17):1547-1558.https://doi.org/10.1056/NEJMoa2214122
4. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes 12 years after localized prostate cancer treatment. NEJM Evid. 2023;2(4). https://doi.org/10.1056/EVIDx2300122
5. Wollersheim BM, van Stam MA, Bosch RJLH, et al. Unmet expectations in prostate cancer patients and their association with decision regret. J Cancer Surviv. 2020;14(5):731–8. https://doi.org/10.1007/s11764-020-00888-6